Press Releases Scientific Reports Videos Press
TR EN
Data Generation Architecture

Data Generation Architecture


Clinical Research Strategy and Data Generation Architecture

Proving the clinical efficacy and biological safety of Bioelectrical Epigenetic Programming (BEP) technology within a framework of rigorous methodological discipline constitutes the foundation of our global clinical research strategy. Designed according to the highest standards of medical requirements, the data generation architecture is structured to produce evidence that is entirely objective, reproducible, and fully compliant with international regulations.

The Validation Design detailed below has been established and implemented to demonstrate the methodological precision and impartial data collection principles within these validation processes:

Validation Design

  • Selection of Extreme and Terminal Clinical Profiles: To validate the efficacy and safety potential of the technology under the most challenging testing conditions, extreme or terminal clinical pathologies are preferred—specifically those with no probability of spontaneous recovery, no established specific curative treatment in current literature, and a mortality rate exceeding 90% under standard care approaches.

  • Absolute Pharmacological Isolation: To ensure that the obtained clinical endpoints and recovery outcomes can be directly and unequivocally attributed to the BEP architecture without confounding factors, all processes have been conducted under absolute pharmacological isolation utilizing monotherapy protocols.

  • Integrated Real-World Data: The stream of clinical evidence is not restricted solely to controlled laboratory environments. The data architecture is structured to integrate dynamic clinical data originating directly from bedside "Real-World Data" domains, encompassing the patient, their caregivers, and the entire matrix of legal and ethical responsibilities.

  • Hypothesis-Agnostic and Double-Blind Research Model: To prevent investigator bias and subjective expectations from affecting data quality, the mechanistic cascade of action of the technology remains blinded to the research teams. All studies are carried out by independent investigators and clinicians using an absolute blinding methodology in full compliance with ISO 14155 (GCP), MDR (EU Medical Device Regulation), and FDA guidelines.

Methodological Standard: In establishing the foundational basis for this paradigm shift in biotechnology, the data architecture adopts the principle that "extraordinary claims require extraordinary evidence." Accordingly, every data point generated possesses an unequivocal transparency that is entirely open to the scrutiny of global medical authorities.